stockrowDr. Reddy's Laboratories Ltd
RDY Healthcare Drug Manufacturers Specialty & Generic
Dr. Reddy's Laboratories Ltd’s revenue for fiscal 2026 (year ended March 2026) was $3.6 billion, down 6.06% from fiscal 2025.
- Revenue
- −10.1%
- EPS
- −36.8%
- Free cash flow
- −70.5%
- Total debt
- +14.1%
Quarter to September 2026, against a year earlier
Follow RDY
Alert me
Dr. Reddy's Laboratories Ltd (RDY) Revenue growth
Dr. Reddy's Laboratories Ltd's revenue growth over the twelve months to 30 September 2026 was −15.5%, down 9.4 percentage points from fiscal 2026 (−6.06%). Over the past ten years it has ranged from −7.02% (fiscal 2017) to 13.8% (fiscal 2025); the current reading is higher than 17% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 5.22% and below the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2026 | −6.06% | (19.82) |
| FY2025 | 13.8% | 1.79 |
| FY2024 | 12.0% | 6.10 |
| FY2023 | 5.87% | (3.07) |
| FY2022 | 8.94% | (3.06) |
| FY2021 | 12.0% | 7.91 |
| FY2020 | 4.09% | 2.07 |
| FY2019 | 2.02% | 1.56 |
| FY2018 | 0.46% | 7.48 |
| FY2017 | −7.02% | (5.21) |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | −10.1% | 4.35 |
| Jun 2026 | −14.4% | 23.12 |
| Mar 2026 | −37.6% | (36.66) |
| Dec 2025 | −0.90% | (7.05) |
| 43 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| KNSA Kiniksa Pharmaceuticals International, plc compare | 58.2% |
| NBIX Neurocrine Biosciences, Inc. compare | 38.0% |
| HIMS Hims & Hers Health, Inc. compare | 28.0% |
| ALKS Alkermes plc compare | 15.3% |
| ELAN Elanco Animal Health Incorporated compare | 12.0% |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | 8.88% |
| VTRS Viatris Inc. compare | 4.27% |
| LNTH Lantheus Holdings, Inc. compare | 2.38% |
| RDY Dr. Reddy's Laboratories Ltd | −15.5% |
| Drug Manufacturers Specialty & Generic industry median | 5.22% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on RDY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement